Cargando…

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia

Treatment of acute myeloid leukemia (AML) remains challenging and novel targets and synergistic therapies still need to be discovered. We performed a high-throughput RNAi screen in three different AML cell lines and primary human leukemic blasts to identify genes that synergize with common antileuke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klosner, Justine, Agelopoulos, Konstantin, Rohde, Christian, Göllner, Stefanie, Schliemann, Christoph, Berdel, Wolfgang E., Müller-Tidow, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639713/ https://www.ncbi.nlm.nih.gov/pubmed/34857808 http://dx.doi.org/10.1038/s41598-021-02695-0

Ejemplares similares

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
por: Aumer, Tina, et al.
Publicado: (2022)

5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia
por: Ebelt, Nancy D., et al.
Publicado: (2022)

In Vivo RNAi Screen Reveals Neddylation Genes as Novel Regulators of Hedgehog Signaling
por: Du, Juan, et al.
Publicado: (2011)

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
por: Schliemann, Christoph, et al.
Publicado: (2016)

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
por: Tibes, Raoul, et al.
Publicado: (2015)

The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report
por: Alrajhi, Abdullah M., et al.
Publicado: (2019)

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia
por: Wang, Yanyu, et al.
Publicado: (2022)

Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: Wang, Wei, et al.
Publicado: (2022)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia
por: Weidenauer, Katharina, et al.
Publicado: (2023)

RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations
por: Brabetz, Oliver, et al.
Publicado: (2017)

Retracted: Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia
por: Sun, Haibo, et al.
Publicado: (2016)

A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia
por: Zhou, Fengbiao, et al.
Publicado: (2023)

Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Angenendt, Linus, et al.
Publicado: (2020)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
por: Berthon, Celine, et al.
Publicado: (2020)

Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia
por: Sun, Haibo, et al.
Publicado: (2017)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
por: Chau, David, et al.
Publicado: (2015)

Retracted: Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

ERG Transcriptional Networks in Primary Acute Leukemia Cells Implicate a Role for ERG in Deregulated Kinase Signaling
por: Bock, Juliane, et al.
Publicado: (2013)

Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia
por: Guo, Naxin, et al.
Publicado: (2019)

Inhibition of NEDD8 NEDDylation induced apoptosis in acute myeloid leukemia cells via p53 signaling pathway
por: Chen, Yanli, et al.
Publicado: (2022)

Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
por: Rohon, Peter, et al.
Publicado: (2012)

Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
por: Xu, Ning, et al.
Publicado: (2021)

The limited contribution of DNA methylation to PML-RARα induced leukemia
por: Rohde, Christian, et al.
Publicado: (2013)

ING1 and 5-Azacytidine Act Synergistically to Block Breast Cancer Cell Growth
por: Thakur, Satbir, et al.
Publicado: (2012)

Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review
por: Katagiri, Takayuki, et al.
Publicado: (2017)

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2018)

5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature.
por: Greco, M., et al.
Publicado: (2011)

Synthesis and Antiproliferative Activities of 5-Azacytidine Analogues in Human Leukemia Cells
por: Guo, Gang, et al.
Publicado: (2008)

Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2016)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine
por: Cabezón, Marta, et al.
Publicado: (2018)

Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study
por: Krug, Utz, et al.
Publicado: (2012)

Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer
por: Chen, Ping, et al.
Publicado: (2015)

Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia
por: Wass, Maxi, et al.
Publicado: (2016)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

Expression of neddylation-related proteins in melanoma cell lines and the effect of neddylation on melanoma proliferation
por: CHENG, FANG, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_c380il1duea7o5oshg0jdavl6i